SCHEMBL2885286

SCHEMBL2885286

COc1cc2c(cc1OC)[C@H]1CCCC[C@H]1N=C2c1ccc(C(=O)c2ccc(C#N)cc2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4D Q08499 5/20 0.46
PDE4B Q07343 5/20 0.46
PDE4A P27815 3/20 0.46
PDE4C Q08493 3/20 0.46
MAPK7 Q13164 1/20 0.39
FASN P49327 3/20 0.37
ALOX5 P09917 1/20 0.36
PTGS2 P35354 1/20 0.36
NR3C2 P08235 2/20 0.36
CHEK1 O14757 2/20 0.36
ROCK2 O75116 1/20 0.35
ROCK1 Q13464 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
ALOX15 P16050 1/20 0.35
CNR1 P21554 1/20 0.35
CASP1 P29466 1/20 0.35
CNR2 P34972 1/20 0.35
CASP7 P55210 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2885287 1.00 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CMAPK7
SCHEMBL2885282 1.00 PDE4D (0.46) PDE4DPDE4BPDE4APDE4CMAPK7
SCHEMBL2887953 0.88 PDE4B (0.49) PDE4DPDE4BPDE4APDE4C
SCHEMBL2887024 0.88 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CMAPT
SCHEMBL2887026 0.88 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CMAPT
SCHEMBL2887949 0.88 PDE4B (0.49) PDE4DPDE4BPDE4APDE4C
SCHEMBL2887955 0.88 PDE4B (0.49) PDE4DPDE4BPDE4APDE4C
SCHEMBL2887030 0.88 PDE4D (0.49) PDE4DPDE4BPDE4APDE4CMAPT
SCHEMBL2883553 0.87 PDE4B (0.48) PDE4DPDE4BPDE4APDE4CROCK2
SCHEMBL2886712 0.87 PDE4B (0.48) PDE4DPDE4BPDE4APDE4CROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776893-B2 Use of PDE4 inhibitors for the treatment of diabetes mellitus NYCOMED GMBH (DE) 2010-08-17 US disclosed
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus ALTANA PHARMA AG (DE) 2006-12-14 US disclosed
EP-1147089-B1 PHENYLPHENANTHRIDINES WITH PDE-IV INHIBITING ACTIVITY ALTANA PHARMA AG (DE) 2005-12-07 EP disclosed
US-6476025-B1 Phenylphennanthridines with PDE-IV inhibiting activity ALTANA PHARMA AG (DE) 2002-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060281745-A1 Use of pde4 inhibitors for the treatment of diabetes mellitus PDE4A, PDE4B, PDE12 PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.